First use of SENSEI® in prostate cancer surgery in the US.
Congratulations to the awesome multi-disciplinary team at @UCLAHealth for first use of our miniature gamma probe, SENSEI®, in the US for robot-assisted prostate cancer surgery.
#PSMA#prostatecancer#surgery#medtech
Tom from University College London, Division of Surgery & Interventional Science, showcased the latest SENSEI® clinical data in robot-assisted prostate cancer surgery and outlined the technology's potential to transform outcomes for colorectal cancer patients.
Great job, Tom!
First-in-woman study shows that SENSEI® is feasible and safe to use for sentinel lymph node detection in cervical cancer patients and highly rated by surgeons for usability in robotic surgery.
The surgical team praised the manoeuvrability and control of SENSEI® compared to conventional rigid laparoscopic gamma probes, particularly the autonomous probe control by the surgeon with the surgical robot.
Dr Adshead has been involved in the development of SENSEI® from very early concept to pre-clinical testing and is a passionate advocate for reducing complications for patients from extended lymph node removal.
Hear the conversation in full: https://t.co/DXEweEf7z1.
@jimadshead
Following our announcement last week detailing the first use of SENSEI® in the US with PSMA at UCLA, listen to Consultant Urological Robotic Surgeon, Dr Jim Adshead, describe how radio-guided PSMA surgery has the potential to transform patient outcomes.
#prostatecancer#urology
Incredibly, in the first case, the team successfully found and removed a tiny (>3mm) metastatic node identified on diagnostic imaging.
When nuclear medicine unites with surgery, amazing things happen!
First use of SENSEI® in prostate cancer surgery in the US.
Congratulations to the awesome multi-disciplinary team at @UCLAHealth for first use of our miniature gamma probe, SENSEI®, in the US for robot-assisted prostate cancer surgery.
#PSMA#prostatecancer#surgery#medtech
The team are pioneering radio-guided robotic surgery for prostate cancer in America, combining SENSEI® and the prostate-cancer-targeted imaging agent, Tc99m-PSMA, to intra-operatively find and remove cancer spread in pelvic lymph nodes.
Next up is the winner of the HealthTech Business of the Year Award...
Congratulations @LightpointMed! 🏆
Presented by Leo Malkin, Partner at @CroweUK#GoTech22 brought to you by @BLeaderNews
Thanks to Dr Lluís Fumadó for presenting at the @AmerUrological 2022 meeting, showing a 100% detection rate of sentinel lymph nodes in prostate cancer surgery with SENSEI®.
To see a SENSEI® procedure performed by Dr Fumadó, visit https://t.co/0PjzOKTaY8
#prostatecancer
Thrilled to be a finalist at this week's Business Leader Go:Tech Awards 2022.
Look forward to seeing everybody on Thursday!
#GoTech22#medtech#innovation @BLeaderNews
SENSEI® named Best New Surgical Technology Solution in the 2022 @MedTech_Awards.
Incredibly proud to be named among giants Medtronic, Abbott, and Boston Scientific: https://t.co/xlxffYtmIb
Find out more at https://t.co/DXEweEf7z1
#medtech#innovation#surgery#nuclearmedicine
Thanks to @ManishChandSurg for his presentation of SENSEI® to The American Association of Colon & Rectal Surgeons #ASCRS22.
Fantastic response from attendees. Great to be collaborating with such a trailblazing surgeon.
Find us at booth 1128 or visit https://t.co/DXEweEf7z1.